Skip to main content
NCBI home page
Elsevier - PMC COVID-19 Collection logoLink to Elsevier - PMC COVID-19 Collection
. 2009 May 13;31(4):784–792. doi: 10.1016/j.clinthera.2009.04.016

Pharmacokinetic properties and bioequivalence of two formulations of arbidol: An open-label, single-dose, randomized-sequence, two-period crossover study in healthy chinese male volunteers

Ming-Yan Liu 1, Shuang Wang 1, Wei-Fan Yao 1, Hui-zhe Wu 1, Sheng-Nan Meng 1, Min-Jie Wei 1,*
PMCID: PMC7133634  PMID: 19446151

Abstract

Background: Arbidol is an antiviral drug indicated for the prevention and treatment of all types of influenza infection and some other kinds of acute respiratory infections, specifically against influenza groups A and B, and severe acute respiratory syndrome. It is used to help prevent influenza infection as long as necessary with little risk for influenza mutation rendering it less effective.

Objective: The aim of this study was to compare the pharmacokinetic properties and tolerability, and to determine bioequivalence, of a newly developed generic dispersible tablet formulation (test) and a branded capsule formulation (reference) of arbidol 200 mg in healthy Chinese fasted male volunteers.

Methods: This open-label, single-dose, randomized-sequence, 2-period crossover study was conducted in healthy native Chinese male volunteers. Eligible subjects were randomly assigned in a 1:1 ratio to receive a single 200-mg dose of the test or reference formulation, followed by a 1-week washout period and administration of the alternate formulation. The study drugs were administered after a 12-hour overnight fast. After the study drug administration, serial blood samples were collected for 72 hours after administration. Plasma drug concentrations were determined using high-performance liquid chromatography coupled with tandem mass spectrometry. Several pharmacokinetic pararameters, including Cmax, Tmax, t½, AUC0-t, and AUC0-∞, were determined from the plasma concentrations of the 2 formulations of arbidol using noncom-partmental analysis. The formulations were to be considered bioequivalent if the log-transformed ratios of Cmax and AUC were within the predetermined bioequivalence range of 80% to 125% established by the State Food and Drug Administration (SFDA) of the People's Republic of China. Tolerability was assessed by monitoring vital signs (blood pressure, heart rate, temperature, and electrocardiography), laboratory analysis (hematology, blood biochemistry, hepatic function, and urinalysis), and subject interview on adverse events.

Results: Twenty subjects were enrolled and completed the study (mean [SD] age, 21.1 [1.1] years; weight, 64.7 [5.1] kg; and height, 172.3 [3.1] cm). Neither period nor sequence effect was observed. The main pharmacokinetic properties with the test and reference formulations were as follows: Cmax, 417.4 (107.6) and 414.8 (95.1) ng/mL, respectively (P = NS); median (range) Tmax, 0.63 (0.25–1.0) and 0.75 (0.5–1.5) hours (P = 0.035); AUC0-t, 2033.6 (564.9) and 1992.0 (483.3) ng/mL/h (P = NS); AUC0-∞, 2285.4 (597.7) and 2215.2 (604.0) ng/mL/h (P = NS); and t1/2, 6.9 (4.2) and 6.1 (5.2) hours (P = NS). The 90% CIs for the log-transformed ratios of Cmax, AUC0-t, and AUC0-∞ were 91.7% to 109.7%, 91.0% to 112.8%, and 92.0% to 116.3%, respectively (all, P < 0.05), which were within the predetermined range for bioequivalence. No adverse events were found on analysis of vital signs or laboratory tests or reported by subjects in this study.

Conclusion: In this study in healthy Chinese male volunteers, the dispersible tablet formulation and the 200-mg capsule formulation of arbidol met the SFDA's regulatory definition of bioequivalence based on the rate and extent of absorption.

Key words: arbidol, bioequivalence, bioavailability, HPLC-MS/MS

References

  • 1.Boriskin YS, Leneva IA, Pécheur EI, Polyak SJ. Arbidol: A broad-spectrum antiviral compound that blocks viral fusion. Curr Med Chem. 2008;15:997–1005. doi: 10.2174/092986708784049658. [DOI] [PubMed] [Google Scholar]
  • 2.Shi L, Xiong H, He J. Antiviral activity of arbidol against influenza A virus, respiratory syncytial virus, rhino-virus, coxsackie virus and adenovirus in vitro and in vivo. Arch Virol. 2007;152:1447–1455. doi: 10.1007/s00705-007-0974-5. [DOI] [PubMed] [Google Scholar]
  • 3.Wang MZ, Cai BQ, Li LY. Efficacy and safety of arbidol in treatment of naturally acquired influenza [in Chinese] Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2004;26:289–293. [PubMed] [Google Scholar]
  • 4.Shuster AM, Shumilov VI, Shevtsov VA. Arbidol used in the prophylaxis of acute respiratory viral infections and their complications in servicemen [in Russian] Voen Med Zh. 2004;325:44–45. [PubMed] [Google Scholar]; Shuster AM, Shumilov VI, Shevtsov VA. Arbidol used in the prophylaxis of acute respiratory viral infections and their complications in servicemen [in Russian] Voen Med Zh. 2004;325:80. [PubMed] [Google Scholar]
  • 5.Kolobukhina LV, Malinovskaia VV, Gatich RZ. Evaluation of the efficacy of wiferon and arbidol in adult influenza [in Russian] Vopr Virusol. 2008;53:80. [PubMed] [Google Scholar]
  • 6.Pécheur EI, Lavillette D, Alcaras F. Biochemical mechanism of hepatitis C virus inhibition by the broad-spectrum antiviral arbidol. Biochemistry. 2007;46:6050–6059. doi: 10.1021/bi700181j. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Boriskin YS, Pécheur EI, Polyak SJ. Arbidol: A broad- spectrum antiviral that inhibits acute and chronic HCV infection. Virol J. 2006;3:56. doi: 10.1186/1743-422X-3-56. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Glushkov RG, Gus'kova TA, Krylova Llu, Nikolaeva IS. Mechanisms of arbidol's immunomodulating action [in Russian] Vestn Ross Akad Med Nauk. 1999:36–40. [PubMed] [Google Scholar]
  • 9.Surinov BP, Karpova NA, Kulish IuS. The immunomodulating properties of arbidol. Pharm Chem J. 1995;29:165–166. [Google Scholar]
  • 10.Zhao C, Zhao Y, Chai H, Gong P. Synthesis and in vitro anti-hepatitis B virus activities of some ethyl 5-hydroxy-1-H-indole-3-carboxylates. Bioorg Med Chem. 2006;14:2552–2558. doi: 10.1016/j.bmc.2005.11.033. [DOI] [PubMed] [Google Scholar]
  • 11.Glushkov RG. Arbidol, antiviral, immunostimulant, interferon inducer. Drugs Future. 1992;17:1079–1081. [Google Scholar]
  • 12.World Medical Association Declaration of Helsinki: Ethical Principles for Medical Research Involving Human Subjects Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964, and amended by the 52nd WMA General Assembly, Edinburgh, Scotland. October 7, 2000 [Google Scholar]
  • 13.European Agency for the Evaluation of Medicinal Products, International Conference on Harmonisation . ICH topic E6. WHO; Geneva, Switzerland: 2002. World Health Organization. Guideline for Good Clinical Practice. [Google Scholar]
  • 14.Metz R, Muth P, Ferger M. Sensitive high-performance liquid chromatographic determination of arbidol, a new antiviral compound, in human plasma. J Chromatogr A. 1998;810:63–69. doi: 10.1016/s0021-9673(97)01006-6. [DOI] [PubMed] [Google Scholar]
  • 15.Liu X, Huang YW, Li J. Determination of arbidol in human plasma by LC-ESI-MS. J Pharm Biomed Anal. 2007;43:371–375. doi: 10.1016/j.jpba.2006.06.039. [DOI] [PubMed] [Google Scholar]
  • 16.State Food and Drug Administration, Center for Drug Evaluation Guideline for bioavailability and bioequiva-lence studies of generic drug products. http://www.cde.org.cn/zdyz.do?method=largePage&id=2066 Accessed January 23, 2009.
  • 17.US Food and Drug Administration. Center for Drug Evaluation and Research (CDER) Guidance for industry, Bio-analytical method validation. http://www.fda.gov/cder/guidance/4252fnl.htm Accessed January 23, 2009.
  • 18.Masterlek Company, Moscow Instructions for the medical use of arbidol. http://www.flucare.org/instructions-for-arbidol.pdf Accessed January 23, 2009.
  • 19.Shijiazhuang No. 4 Pharmaceutical Co Ltd Shijiazhuang. The instructions for the medical use of arbidol hydrochloride capsules. http://www.sjzsiyao.com/upfile/2008-4/200841411922168.pdf Accessed January 23, 2009.
  • 20.Weng JY, Song M, Hang TJ. Pharmacokinetics of HZ08 in rats by liquid chromatography-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;856:29–34. doi: 10.1016/j.jchromb.2007.05.013. [DOI] [PubMed] [Google Scholar]
  • 21.Schuirmann DJ. A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm. 1987;15:657–680. doi: 10.1007/BF01068419. [DOI] [PubMed] [Google Scholar]
  • 22.US Food and Drug Administration, Center for Drug Evaluation and Research Guidance for industry statistical approaches to establishing bioequivalence. http://www.fda.gov/cder/guidance/3616fnl.htm Accessed January 23, 2009.

Articles from Clinical Therapeutics are provided here courtesy of Elsevier

RESOURCES